



Autoimmune diseases: the era of targeted treatments

Autoimmune diseases are diverse and complex diseases involving immune cells, cytokines and protein kinases. In recent years, significant progress has been made in drug development and

targeted therapies for autoimmune diseases, especially biologic drugs. These drugs have primarily focused on monoclonal antibodies and small molecule inhibitors. This infographic provides a comprehensive overview of autoimmune diseases, covering common types, therapeutic targets, drug development, biomarkers, and their applications, while also highlighting Sino Biological's solutions in this field. Common autoimmune diseases













Type 1 **Diabetes**







inflammation and



Sclerosis Damage to the protective covering of nerves, disrupting signals

Ulcerative Colitis Chronic


Destruction of insulin-producing cells in the pancreas








ulcers in the colon and rectum


































Systemic Lupus Erythematosus

SB Sino Biological's top tip!

Certain immune cell proteins play a crucial role in the initiation of aberrant immune responses.

responses, reduce inflammation and tissue damage, thereby controlling disease progression.

Targeting these proteins can modulate the behavior of immune cells to suppress excessive immune

Use reagents designed for the study of your disease of interest. We offer a wide range of research reagents for autoimmune diseases, including each of these examples.

Widespread inflammation affecting multiple systems

CD20

Key therapeutic targets Immune cell proteins

Clinically approved example: The monoclonal antibody ocrelizumab has been approved for multiple scelrosis

Targeting CD20 clears B cells,

reducing autoantibody production


Surface marker on B cells

Co-stimulatory molecule on B cells Targeting CD19 clears B cells and reduces autoimmune responses


Clinically approved example: The

monoclonal antibody inebilizumab has

been approved for neuromyelitis optica



CD19



Clinically approved example: The

approved for rheumatoid arthritis

fusion protein abatacept has been


Key component of the T cell

Clinically approved example: The

monoclonal antibody teplizumab

has been approved for type

receptor complex



Stimulus

CYTOKINE

GENE

Targeting CD3 modulates T cell function and suppresses excessive immune responses

1 diabetes

CD3

- therapeutic strategy which can help regulate immune responses and alleviate disease symptoms.

Effect

🜞 Key factor for B cell survival and activation,

promoting autoantibody production

* Key cytokine for Th17 cell differentiation

TNF-a

Clinically approved example: The Clinically approved example: The monoclonal antibody adalimumab monoclonal antibody belimumab has approved for rheumatoid arthritis been approved for systemic lupus erythematosus

Receptor

Cytokines


Signal

BAFF

IL-23

GENE

ACTIVATION



targeting these kinases help control excessive immune activation and reduce inflammation.

Kinases

B cell receptor

or T cell receptor


JAKs

Clinically approved example: The small molecule inhibitor deuruxolitinib has been approved for alopecia areata

The IAK family regulate immune cell proliferation, differentiation and function by activating

STAT proteins, playing a central role in inflammation and immune regulation

Immune response



protein production. **Main Diseases**

Rheumatoid Arthritis

lot-to-lot consistency.

Castleman disease

Techniques for detection

Sino Biological's top tip!

Improve the reproducibility of your biomarker investigations with our high-quality tools for

Immunofluorescent antinuclear antibody test

This test involves mixing a blood sample with cells, often HEp-2

secondary antibody tagged with fluorescent dye is then added,

These techniques can quantify levels of CRP in a blood sample

Either technique can be used for reliable and accurate detection

of CRP. Immunoturbidimetry is simple to perform, while

cells, whose nuclei are exposed. If ANAs in the sample are

present, they will bind to nuclear antigens on the cells. A

allowing the ANAs to be viewed through a microscope.

Immunoturbidimetry or nephelometry

by measuring the interaction of light with

antigen-antibody complexes.

nephelometry is more sensitive.

biomarker analysis and drug discovery, featuring high activity, purity and

Main Diseases Systemic Lupus Erythematosus Lupus Nephritis IgA Nephropathy

C-Reactive Protein, CRP

immune clearance.

Rheumatoid Arthritis

Complement C3/C4

Main Diseases

Psoriasis

Acute-phase protein sythesized by the liver

damaged cells, activating the complement

system and promoting inflammation and

in response to inflammation or tissue

damage. CRP binds to pathogens or

Systemic Lupus Erythematosus

Central to the complement system, C3

are cleaved into fragments, mediating

inflammation and immune clearance.

participates in the classical, alternative and

lectin pathways, while C4 is involved in the

classical and lectin pathways. Upon, they

This test is often used to detect ANAs as it is a sensitive test that allows for visualization of present ANAs.

ELISA kit This technique uses an enzyme-linked antibody to detect the presence of specific biomarkers, such as IL-6 and C3/C4. This test is often used to detect key biomarkers due to its sensitivity and specificity.

SB Sino Biological's top tip! Don't reinvent the wheel! We offer a range of antibodies and ELIZA kits for biomarker studies. What solutions are available?



Click here to find out more.

Cytokines

* Key pro-inflammatory cytokine that drives inflammation and tissue damage **IL-17** Pro-inflammatory cytokine produced by Th17 cells, driving chronic inflammation

JAK Family

SYK Mediates B cell and Fc receptor signaling, regulating immune cell function by activating downstream signaling pathways. SYK plays a central role in antibody mediated immune responses and inflammation Clinically approved example: The small molecule inhibitor fostamatinib has been approved for purpura

Biomarkers and Applications The primary aim of researching biomarkers in autoimmune diseases is to discover markers that change in response to disease progression but then normalize after effective treatment. They play a critical role in diagnosing diseases, predicting outcomes and monitoring treatment responses. They include cytokines, antibodies, and cellular markers, which reflect the immune system's abnormal activity.

Antinuclear Antibodies, ANA

Systemic Lupus Erythmatosus

Targets nuclear components, forming immune

complexes that activate the immune system

and cause inflammation and tissue damage.

Produced by immune cells, IL-6 binds to IL-6

receptors, activating the JAK-STAT pathway

and promoting inflammation, immune cell

differentiation, and acute-phae

Psoriasis

Main Diseases

Systemic Scleroris

Interleukin-6, IL-6

Sjogren's Syndrome

discovery. Sino Biological, for instance, offers comprehensive reagents for autoimmune disease research, such as recombinant target proteins, cytokines and kinases, supporting pathogenesis study, biomarker analysis, targeted drug discovery and diagnostic kit development.

Solutions are available to assist with autoimmune disease research and drug

SB Sino Biological

This intographic was created as part of a BioTechniques In Focus sponsored by Sino Biological. **Bio**Techniques[®]